The U.S. Food and Drug Administration reversed its position on uniQure N.V.'s gene therapy for Huntington's disease, now allowing a regulatory filing.
This shift provides a potential path toward approval for AMT-130, a treatment targeting a devastating neurodegenerative condition that currently has limited therapeutic options.
The regulatory process for the therapy has been volatile. During a Type A meeting on Jan. 30, 2026 [4], the FDA initially rejected the data from uniQure's Phase I/II studies. That initial rejection caused the company's stock price to plunge 42% [1].
However, the agency shifted its stance in June, concluding that the clinical data were sufficient to support a regulatory submission. This reversal removes the previous requirement for the company to provide additional trial data before proceeding.
uniQure is now targeting a Biologics License Application filing in the third quarter of 2026 [2]. The company expects to release key data in September 2026 [3].
The FDA's decision to grant regulatory flexibility for neurodegenerative treatments allows companies to seek accelerated approval based on a smaller set of clinical markers. This approach is often used for rare diseases where the patient population is small, and the medical need is urgent.
“The FDA reversed its earlier rejection of uniQure's AMT-130 Huntington's disease gene therapy.”
The FDA's reversal signals a willingness to accept surrogate endpoints or early-stage data for high-unmet-need diseases. By allowing uniQure to file for approval without additional trial data, the agency is accelerating the timeline for a potential Huntington's treatment, though the final approval still depends on the September data release.
